SynthesisFrontiers in immunology2026
Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to conduct a systematic review and meta-analysis to investigate how imaging parameters derived from Methods: A comprehensive search was conducted in PubMed, Embase, Cochrane Library, and Web of Science databases to retrieve relevant literature from their inception to December 24, 2024. This study is registered in PROSPERO (CRD42025634694). The protocol was completed in accordance with the PRISMA guidelines recommended by the EJNMMI authors' guide. Cohort studies were included that enrolled patients diagnosed with DLBCL via Results: A total of 14 studies were included, involving 1,088 patients (aged 20 to 86 years) diagnosed with DLBCL based on Conclusion: The outcomes of DLBCL cases managed using CAR-T cells can be effectively predicted using both metabolic metrics from Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier CRD42025634694.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.